title: Therapy-induced secondary acute myeloid leukemia with t(11;19)(q23;p13.1) in a pediatric patient with relapsed acute promyelocytic leukemia.
abstract: Acute myeloid leukemia is classified based upon recurrent cytogenetic abnormalities. The t(15;17)(q24.1;q21.1) abnormality is found in 5% to 8% of de novo acute myeloid leukemia and is diagnostic of acute promyelocytic leukemia (APL). The translocation results in fusion of the retinoic acid receptor-α (RARA) gene at 17q21.1 and the promyelocytic leukemia (PML) gene at 15q24.1. Standard APL therapy is a combination of all-trans retinoic acid and anthracycline-based chemotherapy. Anthracycline treatment is associated with secondary clonal chromosomal aberrations that can lead to therapy-related secondary myeloid neoplasms. We present a pediatric case of relapsed APL coexistent with treatment-associated secondary myeloid neoplasm with t(11;19)(q23;p13.1).
authors.affiliation: *Department of Pathology, Parkland Health and Hospital System, Children's Medical Center ‡Department of Pediatrics, Division of Hematology-Oncology, UT Southwestern Medical Center, Dallas, TX †Department of Pediatrics, Division of Hematology/Oncology, Children's Hospital & Research Center Oakland, Oakland, CA.
authors.forename: Daniel N
authors.initials: DN
authors.lastname: Dang
authors.forename: Heather D
authors.initials: HD
authors.lastname: Morris
authors.forename: James H
authors.initials: JH
authors.lastname: Feusner
authors.forename: Prasad
authors.initials: P
authors.lastname: Koduru
authors.forename: Kathleen
authors.initials: K
authors.lastname: Wilson
authors.forename: Charles F
authors.initials: CF
authors.lastname: Timmons
authors.forename: MaryEllen
authors.initials: M
authors.lastname: Cavalier
authors.forename: Hung S
authors.initials: HS
authors.lastname: Luu
mesh_terms: D018943:Anthracyclines / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002648:Child; D002869:Chromosome Aberrations; D002884:Chromosomes, Human, Pair 15; D002888:Chromosomes, Human, Pair 19; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000235:genetics; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D016609:Neoplasms, Second Primary / Q000235:genetics*; D009687:Nuclear Proteins / Q000235:genetics; D000071156:Promyelocytic Leukemia Protein; D018168:Receptors, Retinoic Acid / Q000235:genetics; D012008:Recurrence; D000072482:Retinoic Acid Receptor alpha; D014157:Transcription Factors / Q000235:genetics; D014212:Tretinoin / Q000008:administration & dosage*; D025521:Tumor Suppressor Proteins / Q000235:genetics
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; C000607071:RARA protein, human; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C070576:PML protein, human; D014212:Tretinoin